Morgan Stanley’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20M | Sell |
1,999,684
-23,304
| -1% | -$211K | ﹤0.01% | 3100 |
|
|
2026
Q1 | $19.3M | Buy |
2,022,988
+277,425
| +16% | +$2.15M | ﹤0.01% | 2999 |
|
|
2025
Q4 | $13.6M | Sell |
1,745,563
-3,457,396
| -66% | -$25M | ﹤0.01% | 3315 |
|
|
2025
Q3 | $39.5M | Sell |
5,202,959
-126,720
| -2% | -$1.06M | ﹤0.01% | 2219 |
|
|
2025
Q2 | $47.8M | Buy |
5,329,679
+3,032,005
| +132% | +$28.2M | ﹤0.01% | 1976 |
|
|
2025
Q1 | $17.2M | Buy |
2,297,674
+631,942
| +38% | +$5.1M | ﹤0.01% | 2847 |
|
|
2024
Q4 | $12.5M | Sell |
1,665,732
-73,348
| -4% | -$557K | ﹤0.01% | 3212 |
|
|
2024
Q3 | $13.2M | Buy |
1,739,080
+161,131
| +10% | +$1.22M | ﹤0.01% | 3208 |
|
|
2024
Q2 | $9.75M | Sell |
1,577,949
-430,096
| -21% | -$2.37M | ﹤0.01% | 3346 |
|
|
2024
Q1 | $10.2M | Sell |
2,008,045
-1,128,643
| -36% | -$6.35M | ﹤0.01% | 3334 |
|
|
2023
Q4 | $18.8M | Buy |
3,136,688
+1,310,864
| +72% | +$7.6M | ﹤0.01% | 2749 |
|
|
2023
Q3 | $12.9M | Buy |
1,825,824
+956,027
| +110% | +$6.87M | ﹤0.01% | 2881 |
|
|
2023
Q2 | $6.12M | Sell |
869,797
-740,873
| -46% | -$5.95M | ﹤0.01% | 3610 |
|
|
2023
Q1 | $13.4M | Buy |
1,610,670
+454,939
| +39% | +$4.38M | ﹤0.01% | 2864 |
|
|
2022
Q4 | $13.3M | Buy |
1,155,731
+246,462
| +27% | +$3.07M | ﹤0.01% | 2778 |
|
|
2022
Q3 | $11.5M | Sell |
909,269
-3,466,300
| -79% | -$44.6M | ﹤0.01% | 2802 |
|
|
2022
Q2 | $46.3M | Buy |
4,375,569
+3,665,522
| +516% | +$37.8M | 0.01% | 1427 |
|
|
2022
Q1 | $11.5M | Buy |
710,047
+333,678
| +89% | +$5.35M | ﹤0.01% | 2749 |
|
|
2021
Q4 | $5.21M | Sell |
376,369
-49,008
| -12% | -$649K | ﹤0.01% | 3677 |
|
|
2021
Q3 | $6.11M | Sell |
425,377
-486,828
| -53% | -$7.68M | ﹤0.01% | 3463 |
|
|
2021
Q2 | $14.4M | Buy |
912,205
+654,998
| +255% | +$8.9M | ﹤0.01% | 2549 |
|
|
2021
Q1 | $2.62M | Sell |
257,207
-17,940
| -7% | -$185K | ﹤0.01% | 4048 |
|
|
2020
Q4 | $2.05M | Buy |
275,147
+81,750
| +42% | +$421K | ﹤0.01% | 4137 |
|
|
2020
Q3 | $664K | Sell |
193,397
-18,996
| -9% | -$81.4K | ﹤0.01% | 4481 |
|
|
2020
Q2 | $1.01M | Sell |
212,393
-479,755
| -69% | -$1.92M | ﹤0.01% | 4157 |
|
|
2020
Q1 | $1.38M | Buy |
692,148
+183,081
| +36% | +$504K | ﹤0.01% | 3685 |
|
|
2019
Q4 | $1.76M | Sell |
509,067
-739,249
| -59% | -$1.86M | ﹤0.01% | 4134 |
|
|
2019
Q3 | $3.58M | Sell |
1,248,316
-164,337
| -12% | -$511K | ﹤0.01% | 3247 |
|
|
2019
Q2 | $5.35M | Buy |
1,412,653
+1,045,869
| +285% | +$6.29M | ﹤0.01% | 2856 |
|
|
2019
Q1 | $2.99M | Buy |
366,784
+183,081
| +100% | +$1.57M | ﹤0.01% | 3223 |
|
|
2018
Q4 | $1.48M | Sell |
183,703
-9,016
| -5% | -$70.1K | ﹤0.01% | 4005 |
|
|
2018
Q3 | $1.47M | Sell |
192,719
-48,610
| -20% | -$326K | ﹤0.01% | 4236 |
|
|
2018
Q2 | $1.38M | Sell |
241,329
-200,102
| -45% | -$1.1M | ﹤0.01% | 4393 |
|
|
2018
Q1 | $2.11M | Buy |
441,431
+52,726
| +14% | +$271K | ﹤0.01% | 3967 |
|
|
2017
Q4 | $1.91M | Buy |
388,705
+26,565
| +7% | +$129K | ﹤0.01% | 4071 |
|
|
2017
Q3 | $1.9M | Buy |
362,140
+44,241
| +14% | +$227K | ﹤0.01% | 3937 |
|
|
2017
Q2 | $1.77M | Sell |
317,899
-156,286
| -33% | -$952K | ﹤0.01% | 3910 |
|
|
2017
Q1 | $3.98M | Buy |
474,185
+146,220
| +45% | +$1.02M | ﹤0.01% | 3106 |
|
|
2016
Q4 | $2.08M | Buy |
327,965
+302,642
| +1,195% | +$1.57M | ﹤0.01% | 3893 |
|
|
2016
Q3 | $112K | Buy |
25,323
+8,529
| +51% | +$34.1K | ﹤0.01% | 5259 |
|
|
2016
Q2 | $48K | Sell |
16,794
-163,431
| -91% | -$507K | ﹤0.01% | 5547 |
|
|
2016
Q1 | $510K | Buy |
180,225
+76,421
| +74% | +$339K | ﹤0.01% | 4431 |
|
|
2015
Q4 | $1.07M | Buy |
103,804
+12,646
| +14% | +$126K | ﹤0.01% | 3999 |
|
|
2015
Q3 | $1.04M | Sell |
91,158
-7,934
| -8% | -$106K | ﹤0.01% | 4074 |
|
|
2015
Q2 | $1.48M | Buy |
99,092
+327
| +0.3% | +$3.72K | ﹤0.01% | 3895 |
|
|
2015
Q1 | $892K | Buy |
98,765
+37,571
| +61% | +$389K | ﹤0.01% | 4217 |
|
|
2014
Q4 | $745K | Sell |
61,194
-227,022
| -79% | -$2.51M | ﹤0.01% | 4368 |
|
|
2014
Q3 | $2.82M | Sell |
288,216
-202,818
| -41% | -$2.49M | ﹤0.01% | 3161 |
|
|
2014
Q2 | $6.26M | Sell |
491,034
-34,272
| -7% | -$333K | ﹤0.01% | 2465 |
|
|
2014
Q1 | $5.56M | Sell |
525,306
-7,706
| -1% | -$82.2K | ﹤0.01% | 2493 |
|
|
2013
Q4 | $4.05M | Buy |
533,012
+458,179
| +612% | +$2.9M | ﹤0.01% | 2768 |
|
|
2013
Q3 | $544K | Sell |
74,833
-104,494
| -58% | -$530K | ﹤0.01% | 4273 |
|
|
2013
Q2 | $278K | Buy |
+179,327
| New | +$309K | ﹤0.01% | 4646 |
|
Other funds holding BCRX
RCM
DM
TCM
PA
JT
VPC
Morgan Stanley's BCRX Position: Q2 2026 in Review
Morgan Stanley reduced its BioCryst Pharmaceuticals (BCRX) stake by 1.2% in Q2 2026, selling an estimated $211K and leaving 1,999,684 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #3100.
Morgan Stanley first reported a position in BCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $47.8M in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.
- Morgan Stanley held 1,999,684 shares of BioCryst Pharmaceuticals worth $20M as of Q2 2026.
- Morgan Stanley sold 23,304 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $211K.
- BioCryst Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3100 holding.
- Morgan Stanley first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's BioCryst Pharmaceuticals position peaked at $47.8M in Q2 2025.
- 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.